Treatment of the Newly Diagnosed Adult with De Noyo Acute Myeloid Leukemia

摘要: Recent studies suggest that the administration of intensive postremission therapy, which includes high-dose cytarabine, results in a longer period disease-free survival when compared with lower dose treatment. In view these improved results, it is uncertain currently whether younger patients acute myeloid leukemia (AML) first remission should be offered such chemotherapy or either allogeneic autologous bone marrow transplantation. Currently ongoing clinical trials, laboratory-based prognostic factor analysis, and attempts at better underStanding pathophysiology may provide more precise guidelines for choosing best treatment among alternatives any given individual AML remission.